LAS VEGAS, NV / ACCESSWIRE / January 19, 2021 / Alkame Holdings, Inc. (OTCPINK:ALKM), a publicly traded health and wellness technology holding company, through its wholly owned subsidiary West Coast Copacker, Inc. is pleased to announce that it has now completed the compliance required to export its premium sanitizer products into Canada.

This milestone allows Alkame to begin shipments of premium bottled gel hand sanitizer as well as our Handout Protection brand of premium individual packets of hand sanitizer and hand wash produced with organic green tea and isopropyl alcohol.

'Finalizing the compliance required from our side allowing us to ship our PPE sanitizer products into Canada is timely as Canadian provinces struggle to contain rising COVID-19 infections' commented Robert Eakle Alkame CEO.

About Alkame Holdings, Inc.

Alkame Holdings, Inc. is a publicly traded health and wellness technology holding company, with a focus on patentable, innovative, and eco-friendly consumer products. The Company's wholly owned subsidiaries manufacture products with enhanced water utilizing a proprietary technology to create products with several unique properties. The organization is diligently building a strong foundation through the launch and acquisition of appropriate business assets, and by pursuing multiple applications by placement into several emerging business sectors, such as consumer bottled water and RTD products, household pet products, horticulture and agriculture applications, hand sanitizers, and many other various water-based treatment solutions to both new and existing business platforms.

For more information, visit www.alkameholdingsinc.com.
Alkame Holdings, Inc. Investor Relations
Website: www.alkameholdingsinc.com
Email: info@alkameholdingsinc.com

Disclaimer/Safe Harbor: This news release contains forward-looking statements within the meaning of the Securities Litigation Reform Act. The statements reflect the Company's current views with respect to future events that involve risks and uncertainties. Among others, these risks include the expectation that Alkame will achieve significant sales, the failure to meet schedule or performance requirements of the Company's contracts, the Company's liquidity position, the Company's ability to obtain new contracts, the emergence of competitors with greater financial resources and the impact of competitive pricing. In the light of these uncertainties, the forward-looking events referred to in this release might not occur. These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure or prevent any disease.

SOURCE: Alkame Holdings, Inc.